今又生联合化疗治疗晚期非小细胞肺癌的安全性和近期疗效观察  

Safety and short-term efficacy of advanced malignant cancer by Gendicine combined with chemotherapy

作　　者：刘艳华[1] 孙丽[1] 孙三元[1] 

机构地区：[1]徐州市中心医院肿瘤内科,江苏221009

出　　处：《齐齐哈尔医学院学报》2015年第36期5470-5472,共3页Journal of Qiqihar Medical University

摘　　要：目的观察今又生(重组人P53腺病毒注射液)联合化疗治疗晚期非小细胞肺癌的安全性及近期疗效。方法选择2011年1月至2013年12月经病理学证实为晚期非小细胞肺癌患者100例,随机分为两组,A组接受今又生联合化疗的治疗方案(治疗组),B组仅接受化疗(对照组)。按照实体瘤的疗效评价标准(RECIST)评估患者的近期的疗效。按照WHO抗癌药物毒副作用分级标准评价毒性反应。结果 A组患者有效率(RR)为48%(24/50),B组为28%(14/50),差异有统计学意义(P=0.039);两组患者的主要不良反应为骨髓抑制和胃肠道反应,发生率无明显差异。治疗组患者出现发热、寒战、肌肉酸痛的几率高于对照组。结论今又生联合化疗治疗晚期非小细胞肺癌近期疗效满意,副反应可耐受,但远期疗效仍需观察。Objective To evaluate the efficacy and safety of Gendicine（ recombinant human adenovirus p53 injection） combined with chemotherapy in patients with advanced non-small cell lung cancer. Methods From January 2011 to December 2013,one-hundred patients with advanced non-small cell lung cancer were randomly divided into two groups. A group was treated with Gendicine and chemotherapy,B group was treated with chemotherapy alone. The curative effect judged with response evaluation criteria in solid tumors（ RECIST）and evaluated toxicity in WHO Toxicity of anticancer drugs classification criteria. Results The objective response rate（ RR） was 48%（ 24 /50） in group A and 24%（ 14 /50） in group B,the difference was statistically significant（ P = 0. 039）. The main adverse reactions of the two groups were myelosuppression and gastrointestinal reactions,with no significant difference in the incidence. The incidence of fever,rigor and muscle ache in the treatment group was higher than the control group. Conclusions It is demonstrated that the use of Gendicine is effective for advanced non-small cell lung cancer and the side effect was mild and acceptable. Long-term outcome requires to be investigated with caution.

关 键 词：晚期非小细胞肺癌 P53腺病毒注射液(rAd-p53) 化学治疗 P53基因 

分 类 号：R734.2[医药卫生—肿瘤]